Spotlight on Infectious Diseases
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19
StartActivity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Infectious Diseases Presentations
No programs are available for this specialty. Check back later.